JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $36

Benzinga Newsdesk www.benzinga.com Positive 71.7%

Neg 0% Neu 0% Pos 71.7%

JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $36.